And We Have a $26.4 Billion Winning Trifecta!

THREE PREVIOUS WINNERS* Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired...

Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...

We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...

Dicerna (DRNA) up 78% Today. Being Acquired by Novo Nordisk (NVO) for $38.00.

We shoot and we score. Up 1,133% since adding to Watch List @ $3.00. Our second...

And We Have Our First MEME Stock! $2.00 to $29.95.

Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg) Guess we were bound to stumble across...

ABVC BioPharma (ABVC) Approved for ABV-1505 Phase II Part II in Taiwan Sites

Gentleman, Start Your Engines? ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study
Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Biotech Stock Review, DYAI

Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).

Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal. We've had...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE
@bryteeyes3

Citius (CTXR). Dang Flippers!

Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
@NCI

Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...

- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...

Latest article

Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!

When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...

GeoVax to Provide Corporate Update on Tuesday May 14, 2024.

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...

NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...

Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...